Research firm Zacks has rated Glaxosmithkline Plc (NYSE:GSK) and has ranked it at 5, indicating that for the short term the shares are a strong sell. 8 Wall Street analysts have given the company an average rating of 2.63. The counter has received a hold rating based on the suggestion from 5 analysts in latest recommendations. 1 market expert has a sell on the stock. Strong buy was given by 2 Wall Street Analysts.
GlaxoSmithKline PLC (NYSE:GSK): 2 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $48.5 in GlaxoSmithKline PLC (NYSE:GSK). However, the stock price could fluctuate by $ 4.95 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $52 price target with the lower price estimate is calculated at $45
The stock has received coverage from different analysts. Equity analysts at the Brokerage firm New Street Research downgrades its rating on GlaxoSmithKline PLC (NYSE:GSK). On July 3, 2014 The shares registered one year high of $54.78 and one year low was seen on January 6, 2015 at $41.25 The 50-day moving average is $45.97 and the 200 day moving avarge is recorded at $45.65. S&P 500 has rallied 9.48% during the last 52-weeks.
Shares of GlaxoSmithKline PLC (NYSE:GSK) ended Monday session in red amid volatile trading. The shares closed down 0.22 points or 0.5% at $44.15 with 3,004,537 shares getting traded. Post opening the session at $44.41, the shares hit an intraday low of $44 and an intraday high of $44.46 and the price vacillated in this range throughout the day. The company has a market cap of $107,422 million and the number of outstanding shares has been calculated to be 2,433,104,000 shares. The 52-week high of GlaxoSmithKline PLC (NYSE:GSK) is $54.78 and the 52-week low is $41.25.
Source: OTC Outlook